ReviewCurrent opinion in microbiology2012
Recent progress in vaccines against fungal diseases.
Review in Current opinion in microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Guideline
- Advances in Fungal Infection Research: From Novel Diagnostics to Innovative Therapeutics.Journal of fungi (Basel, Switzerland) · 2025Article
- Antifungal Innate Immunity.Advances in experimental medicine and biology · 2025Review
- Bioinformatics-Driven mRNA-Based Vaccine Design for Controlling Tinea Cruris Induced byPharmaceutics · 2024Article
- Exploiting antifungal immunity in the clinical context.Seminars in immunology · 2023Review
- Vaccines against candidiasis: Status, challenges and emerging opportunity.Frontiers in cellular and infection microbiology · 2022Review
- Vulvovaginal Candidosis (Excluding Mucocutaneous Candidosis): Guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SGGG) Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry Number 015/072, September 2020).Geburtshilfe und Frauenheilkunde · 2021Article
- Disseminated Coccidioidomycosis of the Knee Joint Requiring Synovectomy and Arthrotomy.Journal of orthopaedic case reports · 2021Article
- Interactions of Extracellular Vesicles from Pathogenic Fungi with Innate Leukocytes.Current topics in microbiology and immunology · 2021Article
- Vaccine-Induced Immunological Memory in Invasive Fungal Infections - A Dream so Close yet so Far.Frontiers in immunology · 2021Review
- Advances in Fungal Peptide Vaccines.Journal of fungi (Basel, Switzerland) · 2020Review
- Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies.Journal of fungi (Basel, Switzerland) · 2020Review
- Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections.Frontiers in cellular and infection microbiology · 2020Review
- Carbohydrate Conjugates in Vaccine Developments.Frontiers in chemistry · 2020Review
- Immunomodulation as a Therapy forJournal of fungi (Basel, Switzerland) · 2018Review
- An unappreciated role for neutrophil-DC hybrids in immunity to invasive fungal infections.PLoS pathogens · 2018Article
- Immunization with Pneumocystis Cross-Reactive Antigen 1 (Pca1) Protects Mice against Pneumocystis Pneumonia and Generates Antibody to Pneumocystis jirovecii.Infection and immunity · 2017Article
- Methods of Controlling Invasive Fungal Infections Using CD8Frontiers in immunology · 2017Review
- Mitigating amphibian chytridiomycoses in nature.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2016Review
- Immunological Outcomes of Antibody Binding to Glycans Shared between Microorganisms and Mammals.Journal of immunology (Baltimore, Md. : 1950) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Diseases caused by fungi are increasingly impacting the health of the human population and now account for a large fraction of infectious disease complications in individuals with impaired immunity or breached tissue defenses. Antifungal therapy is often of limited effectiveness in these patients, resulting into treatment failures, chronic infections and unacceptable rates of mortality, morbidity and their associated costs. Consequently there is a real medical need for new treatments and preventive measures to combat fungal diseases and, toward this goal, safe and efficacious vaccines would constitute major progress. After decades of complacency and neglect of this critically important field of research, remarkable progress has been made in recent years. A number of highly immunogenic and protective vaccine formulations in preclinical setting have been developed, and at least two have undergone Phase 1 clinical trials as preventive and/or therapeutic tools against candidiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.